{
    "Clinical Trial ID": "NCT00148668",
    "Intervention": [
        "干预一:",
        "手臂 1",
        "黑塞普丁/纳维尔宾",
        "干预2:",
        "手臂2",
        "卡博普拉丁 / Herceptin"
    ],
    "Eligibility": [
        "融入标准:",
        "乳腺癌第二或第三阶段的患者",
        "HER2 阳性肿瘤",
        "18岁以上的老年人",
        "东方合作肿瘤学小组(ECOG)绩效状态大于或等于1。",
        "ANC > 1500/mm3",
        "血液含量 > 9gm/dl",
        "板块 > 100,000mm3",
        "创造素 < 2mg/dl",
        "葡萄糖 < 200mg/dl",
        "比利鲁宾 < 1.5 x ULN",
        "排除标准:",
        "以前使用赫塞普丁,计量素,多克索鲁比辛或其他类似于安特拉西克林的疗法,或基于的疗法。",
        "孕妇或母乳喂养妇女",
        "严重的疾病,或医疗或精神疾病",
        "未经控制的感染",
        "活跃或严重的心血管或肺部疾病",
        "左腹部排泄率 < 50% 的患者",
        "任何病理超出1级的周边神经病理",
        "早期恶性病史",
        "未经控制的糖尿病"
    ],
    "Results": [
        "测量结果:",
        "Herceptin/Navelbine versus Taxotere/Carboplatin/Herceptin在HER-2阳性早期乳腺癌患者前手术治疗后的病理综合反应",
        "病理完整反应定义为在手术时在乳房中侵入性肿瘤完全消失。",
        "时间框架:12周",
        "结果一:",
        "手臂名称:手臂1",
        "手臂/组 描述: Herceptin/navelbine",
        "分析的参与者总数: 41",
        "尺寸类型: 数字",
        "测量单位:参与者百分比 17",
        "结果二:",
        "名称:手臂2",
        "手臂/组 描述: Taxotere/carboplatin/herceptin",
        "分析参与者总数:39人",
        "尺寸类型: 数字",
        "测量单位:参与者百分比 31"
    ],
    "Adverse Events": [
        "意外事件一:",
        "总数: 5/41 (12.20%)",
        "中性衰竭 4/41 (9.76%)",
        "发烧性中毒性 0/41 (0.00%)",
        "SGPT(ALT) 1/41 (2.44%)",
        "不利事件二:",
        "总数: 5/40 (12.50%)",
        "内分裂症 4/40 (10.00%)",
        "发烧性中毒性 1/40 (2.50%)",
        "SGPT(ALT) 0/40 (0.00%)"
    ]
}